Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC

NCT04723004 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

326

Enrollment

OTHER

Sponsor class

Conditions

Advanced Hepatocellular Carcinoma (HCC)

Interventions

COMBINATION_PRODUCT: Toripalimab combined with Bevacizumab
DRUG: Sorafenib

Sponsor

Shanghai Junshi Bioscience Co., Ltd.